TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06312228

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Helfer Skin Tap
Description: Slow tapping was performed with rhythmic tapping movements on the left deltoid muscle where the vaccine will be administered to the children. When the needle was to be inserted into the deltoid muscle, the tapping was slightly increased and the needle entry was made with the same movement. After the vaccine injection was given, the needle was rapidly withdrawn from the muscle by increasing the tapping movements while the needle was withdrawn.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Buzzy
Description: The ice pack previously removed from the deep freezer was kept at room temperature for 10 minutes and the hole in the ice pack wing was placed on the hook behind the Buzzy®. The Buzzy® was placed on the left arm deltoid muscle and activated and kept for 30 seconds. After 30 seconds, Buzzy® was pulled up 1 centimetre (cm) and the MMR vaccine injection was administered to the area corresponding to the left deltoid muscle. After the vaccine injection, Buzzy® was pulled to the injection site and kept for another 30 seconds.
Study: NCT04939610

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAP-2286
Description: 68Ga-FAP-2286 IV administered as imaging agent for PET scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-FAP-2286
Description: 68Ga-FAP-2286 IV administered as imaging agent for PET scan.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-FAP-2286
Description: Phase 1:~Patients with positive uptake of 68Ga-FAP- 2286 will receive a fixed dose of 177Lu-FAP-2286 IV administered every 6 weeks for a maximum of 6 doses. Doses range between 3.7 and 9.25 GBq (100-250 mCi).~Phase 2:~Monotherapy: Patients with positive uptake of 68Ga FAP 2286 will receive a fixed dose of 177Lu FAP 2286 IV administered at the RP2D determined in Phase 1 dose escalation in every 4 weeks.~Combination therapy: Patients with positive uptake of 68Ga FAP 2286 will receive 177Lu-FAP-2286 based on dose escalation (starting with dose level 1) followed by dose expansion at selected dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 177Lu-FAP-2286
Description: Phase 1:~Patients with positive uptake of 68Ga-FAP- 2286 will receive a fixed dose of 177Lu-FAP-2286 IV administered every 6 weeks for a maximum of 6 doses. Doses range between 3.7 and 9.25 GBq (100-250 mCi).~Phase 2:~Monotherapy: Patients with positive uptake of 68Ga FAP 2286 will receive a fixed dose of 177Lu FAP 2286 IV administered at the RP2D determined in Phase 1 dose escalation in every 4 weeks.~Combination therapy: Patients with positive uptake of 68Ga FAP 2286 will receive 177Lu-FAP-2286 based on dose escalation (starting with dose level 1) followed by dose expansion at selected dose.
Study: NCT06118866

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo-Q2W
Description: placebo, 0mg，SC，Q2W，12 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HMI-115-120mg-Q4W
Description: HMI-115, 120mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HMI-115-240mg-Q4W
Description: HMI-115, 240mg，SC，Q4W，6 cycles(Placebo given in the second week of each cycle)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HMI-115, 240mg-Q2W
Description: HMI-115, 240mg，SC，Q2W，12 cycles
Study: NCT05294978

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography (OCT)
Description: Data of macular optical coherence tomography (OCT)

Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography (OCT)
Description: Data of macular optical coherence tomography (OCT)
Study: NCT04892823

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample

Intervention type: OTHER
Intervention: Electronic Health Record Review
Description: Review of medical records

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT05611151

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Computer Aided Detection (CADe)
Description: Computer-aided detection (CADe) devices are used in conjunction with colonoscopy to aid in the detection of lesions in the gastrointestinal tract.

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Computer Aided Detection (CADe)
Description: Computer-aided detection (CADe) devices are used in conjunction with colonoscopy to aid in the detection of lesions in the gastrointestinal tract.
Study: NCT05782283

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ACE (AI-Cirrhosis-ECG) 2.0
Description: An electrocardiogram (ECG) based artificial intelligence (AI) powered tool for detection of undiagnosed cirrhosis in primary care practices. And email alert is sent to providers which will display whether the ACE 2.0 result is positive or negative for the likelihood of advanced liver disease.
Study: NCT04945746

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: AF ablation
Description: AF ablation using the Volta Medical VX1 CE marked software and a new criteria to establish a priority of the dispersed zones according to the stability of the core algorithm's response (thanks to the new software module under study named stability).
Study: NCT05363020

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: S-Adenosyl-L-Methionine (Sam-E)
Description: 400 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-Adenosyl-L-Methionine (Sam-E)
Description: 400 mg capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 400 mg identically appearing placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 400 mg identically appearing placebo
Study: NCT06399900

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Far red light therapy
Description: All participants will receive one far red light device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. An unblinded study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham light therapy
Description: All participants will receive one sham device per leg. Participants will be asked to use their two light devices daily, exposing their bare legs to the devices for 10 minutes twice per day. An unblinded study coordinator will deliver the light devices to each participant's home, positioning the devices 15 cm behind the participant's heels, using tape on the floor to mark where the light and feet should be positioned. Twice each day, the participant flips a switch on the device to begin each session. A timer will turn off the device after 10 minutes. A power meter will measure the total time that the device was turned on. Participants will also record use of the light in a log.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home-based walking exercise
Description: This study involves a 16 week intervention where participants will walk at home for exercise with guidance from a study coach. Participants will have 4 in-person visits in the first four weeks and then have weekly phone calls in the last 12 weeks of the intervention with their coach.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Home-based walking exercise
Description: This study involves a 16 week intervention where participants will walk at home for exercise with guidance from a study coach. Participants will have 4 in-person visits in the first four weeks and then have weekly phone calls in the last 12 weeks of the intervention with their coach.
Study: NCT05206708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized psychotherapy
Description: Strategy including personalized psychotherapy

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Strategy based standard intregrative psychodynamic therapy
Study: NCT05665738

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High Dose Rate Monotherapy
Description: High dose rate brachytherapy delivered in 13.5 Gy x 2 fractions over a single implant procedure 3 hours apart
Study: NCT06041763

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Meniscal Repair Procedure
Description: All meniscal repairs will be performed by the surgeons who are listed as investigators for the study. Meniscal repair consists of arthroscopic suturing of torn fragments. This takes approximately 20 minutes. In the interventional group, the BEAR implant will be inserted through preexistent arthroscopic portals after repair is complete. This will take an additional 2 minutes.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Meniscal Repair Procedure
Description: All meniscal repairs will be performed by the surgeons who are listed as investigators for the study. Meniscal repair consists of arthroscopic suturing of torn fragments. This takes approximately 20 minutes. In the interventional group, the BEAR implant will be inserted through preexistent arthroscopic portals after repair is complete. This will take an additional 2 minutes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BEAR Implant
Description: The BEAR Implant (22 mm in diameter and 45mm in length) is cylindrical in shape and comprised of collagen and extracellular matrix derived from bovine connective tissue, which has been cleaned, disinfected and processed by a proprietary manufacturing method. The implant has been terminally sterilized by electron-beam inadiation and is intended to be used with up to 10 ml of autologous blood drawn during the surgical implantation procedure. The BEAR Implant is resorbed within 8 weeks and replaced with a fibrovascular repair tissue.
Study: NCT06234228

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Bluetooth Haptic Device (BHD)
Description: The BHD will deliver constant low-frequency vibration (CF).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BHD synced with mobile game
Description: The BHD delivers a constant low-frequency vibration as well as tactile feedback from the game (GF).
Study: NCT05052125

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Administering oxygen to achieve the desired peripheral oxygen saturation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Administering oxygen to achieve the desired peripheral oxygen saturation
Study: NCT04880980

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Terbinafine Pill
Description: Double than usual dose of oral terbinafine pills will be used for treatment purpose in one group.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole capsule
Description: Double than usual dose of oral itraconazole capsules will be used for treatment purpose in second group.
Study: NCT04838782

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repeat Surgical Management of Recurrent GBM
Description: Routine of surgical operative management. Details of treatment will be left to local centers, and recorded in the case report form (CRF).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repeat Surgical Management of Recurrent GBM
Description: Routine of surgical operative management. Details of treatment will be left to local centers, and recorded in the case report form (CRF).
Study: NCT05418179

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic
Description: Probiotic (Bifidobacterium animalis subsp. Lactis, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus gasseri, Lactobacillus casei, Lactobacillus rhamnosus) - 1 capsule/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin (1 capsule/day)
Study: NCT06016803

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cicatryl (RL3010A - DP0378)
Description: Tested product is applied twice a day. The maximum duration of application is 7 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cicatryl (RL3010A - DP0378)
Description: Tested product is applied twice a day. The maximum duration of application is 7 days.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cicatryl (RL3010A - DP0378)
Description: Tested product is applied twice a day. The maximum duration of application is 7 days.
Study: NCT06121102

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Supervoltage pulsed radiofrequency glossopharyngeal nerve block
Description: Stimulation will be done using baylis generator both sensory at 50 HZ and 0.5-1.0 V (patient felt tingling at base of tongue, throat, ear and side of upper neck) and motor at 2 HZ and 1-2 V (contraction of stylopharyngeus muscle will be felt). After injecting 1 ml lidocaine 2% plus 1 ml (4 mg) Betamethasone (Diprofos) to augment analgesia and to lower impedance (usually it was 200-300 ohm due to bony proximity).Super voltage pulsed RF(60-75 volt according to patient tolerability will be done for 8 minutes with pulse width = 5 millisecond and pulse frequency of 2 HZ.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard voltage pulsed radiofrequency glossopharyngeal nerve block
Description: Stimulation will be done using baylis generator both sensory at 50 HZ and 0.5-1.0 V (patient felt tingling at base of tongue, throat, ear and side of upper neck) and motor at 2 HZ and 1-2 V (contraction of stylopharyngeus muscle will be felt). After injecting 1 ml lidocaine 2% plus 1 ml (4 mg) Betamethasone (Diprofos) to augment analgesia and to lower impedance (usually it was 200-300 ohm due to bony proximity).Super voltage8 pulsed RF will be done for 8 minutes with pulse width = 5 millisecond and pulse frequency of 2 HZ.
Study: NCT05288153

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Subjects will be instructed to take one tablet(500mg) of metformin after breakfast every day, and to visit the hospital every 4 weeks for evaluation of the subjective symptoms and for receiving a new supply of medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Folate
Description: Subjects will be instructed to take one tablet(5mg) of folate three times every day, and to visit the hospital every 4 weeks for evaluation of the subjective symptoms and for receiving a new supply of medication.
Study: NCT06337084

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNPR-101-DFO*-89Zr
Description: Participants will receive one dose of MNPR-101-DFO\*-89Zr infused intravenously on Day 1 for PET scans

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/CT Diagnostic Imaging
Description: PET/CT imaging will occur post-infusion at 2 h (Day 1), once on Days 3-5, and once on Days 7-10 for tumor lesion observation.
Study: NCT06479642

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Genicular nerve pulse radiofrequency ablation 3
Description: Ultrasound-guided genicular nerve radiofrequency therapy targets only the traditional 3 genicular nerves

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Genicular nerve pulse radiofrequency ablation 4
Description: Ultrasound-guided genicular nerve radiofrequency therapy targets only the traditional 3 genicular nerves and the intermedius genicular nerve in addition to the traditional genicular nerves.
Study: NCT05572255

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: 200 mg Cenobamate Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: 200 mg Cenobamate Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenobamate
Description: 200 mg Cenobamate Tablet
Study: NCT06554574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LTG-305
Description: Part A: Single-Ascending dose cohorts; Part B: Multiple-ascending dose cohorts

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LTG-305
Description: Part A: Single-Ascending dose cohorts; Part B: Multiple-ascending dose cohorts
Study: NCT05488678

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-7145
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-7145
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-7145
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-7145
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VNRX-7145
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftibuten
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftibuten
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftibuten
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftibuten
Description: single oral dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftibuten
Description: single oral dose
Study: NCT06079697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Electronic Health Record Review
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise Intervention
Description: Receive prehabilitation exercise intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Medical Device Usage and Evaluation
Description: Wear Fitbits

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medical Device Usage and Evaluation
Description: Wear Fitbits

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT06210646

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citicoline 2000
Description: The citicoline arm consists of 400 patients who received 2000 mg citicoline once daily for 12 months, and an open-label double antiplatelet in the form of 75 mg aspirin, and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citocoline 1000
Description: The placebo arm consists of 400 patients who received a citicoline 1000 mg once daily for 12 months, an open-label double antiplatelet in the form of 75 mg aspirin, and 75 mg clopidogrel for three weeks, followed by a single antiplatelet in the form of 75 mg clopidogrel for the rest of our trial.
Study: NCT04960189

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture will be performed bilateral on fibular aspect of the leg, in the depression anterior and distal to the head of the fibula by using 0,25x50mm needles.
Study: NCT05696301

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Winback® on
Description: For this study, we will use only the instrumental mode and the 4-cm electrodes. During each session, this electrode will be moved over the entire scar, with the contact between electrode and the skin provided by an adequate quantity of conductive cream.~We will use the following 3 modes: CET, CET Dynamic, and RET; these allow us to standardize the treatment without taking into account either the thickness of the abdominal wall or the woman's morphology.~Each session will take 20 minutes (CET for 4 min, CET Dynamic 6 min, RET 6 min and CET 4 min). The intensity of CET and RET will be adapted to each woman and the diathermy chosen according to the woman's threshold of comfort, to be determined by her at each session.~There will be 1 session a week for 3 weeks. Portable instrument is activated.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Winback® off
Description: For this study, we will use only the instrumental mode and the 4-cm electrodes. During each session, this electrode will be moved over the entire scar, with the contact between electrode and the skin provided by an adequate quantity of conductive cream.~We will use the following 3 modes: CET, CET Dynamic, and RET; these allow us to standardize the treatment without taking into account either the thickness of the abdominal wall or the woman's morphology.~Each session will take 20 minutes (CET for 4 min, CET Dynamic 6 min, RET 6 min and CET 4 min). The intensity of CET and RET will be adapted to each woman and the diathermy chosen according to the woman's threshold of comfort, to be determined by her at each session.~There will be 1 session a week for 3 weeks. Portable instrument is not activated.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: self-massage of the scar
Description: The women in both groups will have the standard recommended treatment: manual self-massage of the scar. Women's instruction in this self-massage will be structured and identical for both groups, including the provision of an informational document describing how to perform the massage. This training will be provided immediately after randomization and before the intervention or control measures.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: self-massage of the scar
Description: The women in both groups will have the standard recommended treatment: manual self-massage of the scar. Women's instruction in this self-massage will be structured and identical for both groups, including the provision of an informational document describing how to perform the massage. This training will be provided immediately after randomization and before the intervention or control measures.
Study: NCT05973695

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: clamshell exercise
Description: For clamshell exercises, Lie on your side with your knees slightly bent and with one leg on top of the other. Keep your feet together and lift your top knee until its parallel with your hip. Lower your knee back to the initial position, repeat, and then switch sides. In 1st week 1 sets 10 repetitions. In 2nd week 2 sets of 10 repetitions. In 3rd and 4th week and onwards 3 sets of 10 repetitions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Gluteal Bridge exercises
Description: Start flat on your back with your legs bent at a 90-degree angle and feet placed flat on the ground. Make sure your toes are turned outward at 45-degree angles and your knees are facing in the same direction as your toes. Drive d
Study: NCT05778669

Intervention type: OTHER
Intervention: Monitoring of medical, health and psychosocial conditions
Description: Questionnaires will be used to collect information including children's health and psychosocial conditions, academic performance, and family demographics.~On-site assessments including general health and learning assessments.~Tracking of medical and health-related events of participants will be performed through the existing health care system.